CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 10, 2025
-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine-
Read more at globenewswire.com
